Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen

Houreratou Barry, Edouard Lhomme, Mathieu Surénaud, Moumini Nouctara, Cynthia Robinson, Viki Bockstal, Innocent Valéa, Serge Somda, Halidou Tinto, Nicolas Méda, Brian Greenwood, Rodolphe Thiébaut, Christine LacabaratzmedRxiv 2023 · DOI

Abstract

There is a well-documented "geographic gap" in vaccine performance, where populations in sub-Saharan Africa often mount lower immune responses compared to those in Europe or North America. One leading hypothesis suggests that chronic exposure to parasitic worms (helminths) modulates the host immune system, potentially dampening vaccine efficacy. This study evaluated the association between helminth exposure and the immune response to the two-dose heterologous Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) using samples from three international clinical trials (EBL2001, EBL2002, and EBL3001). While helminth exposure was associated with significant changes in baseline inflammatory and activation markers, it did not significantly impair the concentration of Ebola virus glycoprotein (EBOV GP) binding antibodies post-vaccination. These findings suggest that the Ad26.ZEBOV, MVA-BN-Filo regimen is robust against the immunomodulatory effects of helminth pre-exposure.

Introduction

Vaccine efficacy often varies by geography, with lower immunogenicity frequently observed in tropical, low-income regions. The "helminth hypothesis" posits that endemic parasitic infections reprogram the human immune system toward a Th2-biased and regulatory environment to facilitate parasite survival. This environment may, in turn, suppress the Th1-type responses typically required for effective viral vaccines. This study investigates whether such exposure influences the response to the Janssen Ebola vaccine regimen, which has been critical in managing recent outbreaks.

Methods

The researchers conducted a cross-sectional analysis of serum samples from 367 participants across three major clinical trials:

  • EBL2001: Participants in the UK and France.
  • EBL2002: Participants in Burkina Faso, Côte d’Ivoire, Kenya, and Uganda.
  • EBL3001: Participants in Sierra Leone.

Helminth exposure was assessed via ELISA, detecting IgG antibodies against Schistosoma mansoni, Acanthocheilonema viteae, and Strongyloides ratti. Additionally, Luminex technology was employed to measure 41 baseline immunological analytes (cytokines and chemokines). The primary outcome was the concentration of IgG antibodies specific to the Ebola virus glycoprotein (EBOV GP), measured 21 days after the second dose and one year after the first dose.

Key Results

Prevalence and Baseline Immune Profiles

Of the 367 participants, 21.3% (n=78) tested positive for at least one helminth marker at baseline. Prevalence varied significantly by geography, peaking at 34% in Uganda compared to 9.4% in the UK.

Helminth-positive individuals exhibited a distinct baseline immune profile. Five markers were significantly lower (p < .003) in these participants: CCL2/MCP1, FGFbasic, IL-7, IL-13, and CCL11/Eotaxin. The reduction in IL-7 (a T-cell growth factor) and IL-13 (a Th2 cytokine) confirms that parasitic exposure actively modulates the host's systemic immune environment prior to vaccination.

Vaccine Immunogenicity

Despite the altered baseline immune states, the vaccine regimen remained highly effective. Multivariable linear regression models, adjusted for age and study group, found no significant association between helminth exposure and EBOV GP antibody concentrations at either 21 days post-dose 2 (p = 0.19) or one year post-dose 1 (p = 0.85).

Geographic and Demographic Factors

While helminths did not explain the variance, geography remained a significant factor; European participants generally mounted higher antibody responses than African participants even after adjusting for helminth status. Additionally, age was a strong predictor of response, with children mounting higher antibody concentrations than adults.

Discussion and Conclusion

This study demonstrates that while helminth exposure significantly alters the baseline inflammatory landscape, it does not appear to be the primary driver of the geographic gap in Ebola vaccine response. The Ad26.ZEBOV, MVA-BN-Filo regimen appears robust enough to overcome the immunomodulatory environment associated with helminth pre-exposure.

Limitations of the study include the use of antibody-based ELISA tests, which may indicate past exposure rather than active, current infection. Future research into the geographic variability of vaccine responses should shift focus toward other environmental factors, such as the gut microbiota, nutrition, or other co-infections like malaria, which may play a more decisive role in shaping vaccine-induced immunity.

Summary updated

Abstract

Abstract Background The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and European participants using samples obtained from three international clinical trials. Methods/Principal Findings We conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EVD in children, adolescents and adults from the United Kingdom, France, Burkina Faso, Cote d’Ivoire, Kenya, Uganda and Sierra Leone. Immune markers of helminth exposure at baseline were evaluated by ELISA with three commercial kits which detect IgG antibodies against schistosome, filarial and Strongyloides antigens. Luminex technology was used to measure inflammatory and activation markers, and Th1/Th2/Th17 cytokines at baseline. The association between binding IgG antibodies specific to EBOV GP (measured on day 21 post-dose 2 and on Day 365 after the first dose respectively), and helminth exposure at baseline was evaluated using a multivariable linear regression model adjusted for age and study group. Seventy-eight (21.3%) of the 367 participants included in the study had at least one helminth positive ELISA test at baseline, with differences of prevalence between studies and an increased prevalence with age. The most frequently detected antibodies were those to Schistosoma mansoni (10.9%), followed by Acanthocheilonema viteae (9%) and then Strongyloides ratti (7.9%). Among the 41 immunological analytes tested, five were significantly (p&lt;.003) lower in participants with at least one positive helminth ELISA test result: CCL2/MCP1, FGFbasic, IL-7, IL-13 and CCL11/Eotaxin compared to participants with negative helminth ELISA tests. No significant association was found with EBOV-GP specific antibody concentration at 21 days post-dose 2, or at 365 days post-dose 1, adjusted for age group, study, and the presence of any helminth antibodies at baseline. Conclusions/Significance No clear association was found between immune markers of helminth exposure as measured by ELISA and post-vaccination response to the Ebola Ad26.ZEBOV/ MVA- BN-Filo vaccine regimen. Author Summary Recurrent exposure to parasites may influence the immune response to vaccines, especially in endemic African countries. In this study we aimed to assess the association between immune markers of helminth exposure and the immune response post-vaccination with the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in African and European participants who participated in three international clinical trials. Seventy-eight (21.3%) of the 367 participants included in the study, had at least one helminth ELISA positive test at baseline with differences of prevalence between studies and an increased prevalence with increasing age. After adjustment for confounding factors, the study did not show a clear association between immunological markers of helminth exposure and the antibody concentration in response to the Ebola vaccine regimen.
BibTeX
@misc{barry2023helminth,
  author = {Houreratou Barry and Edouard Lhomme and Mathieu Surénaud and Moumini Nouctara and Cynthia Robinson and Viki Bockstal and Innocent Valéa and Serge Somda and Halidou Tinto and Nicolas Méda and Brian Greenwood and Rodolphe Thiébaut and Christine Lacabaratz},
  title = {{Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen}},
  year = {2023},
  doi = {10.1101/2023.07.05.23292287},
  howpublished = {medRxiv},
}
Figure